Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Industry M&A volume declined 8% this year compared to '23
Fierce Biotech
Thursday, December 12, 2024 - 11:43am
tags:
M&A, PwC
Patterson, a dental products distributor, agrees to $4.1B sale to healthcare investor
Medtech Dive
Thursday, December 12, 2024 - 11:38am
tags:
Patterson Companies, dental, M&A, Medtech
Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line
Fierce Biotech
Thursday, December 12, 2024 - 11:38am
tags:
Tenpoint Therapeutics, Visus Therapeutics, presbyopia, M&A
Pfizer's Ibrance improves survival in new breast cancer indication
BioSpace
Thursday, December 12, 2024 - 11:35am
tags:
Pfizer, Ibrance, clinical trials, breast cancer
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Pharma Voice
Thursday, December 12, 2024 - 11:33am
tags:
ASH 2024, Regeneron, lymphoma, Alexion, Ultomiris
NIH abandons trial of SIGA's mpox drug
Pharmaphorum
Thursday, December 12, 2024 - 11:31am
tags:
SIGA technologies, mpox, NIH, clinical trials, Tecovirimat
Lonza plans to shed capsules business, simplify operating structure in push to become 'pure-play' CDMO
Fierce Pharma
Thursday, December 12, 2024 - 11:30am
tags:
Lonza, CDMOs, drug manufacturing
Lynparza boosts long-term survival in early breast cancer
Pharmaphorum
Thursday, December 12, 2024 - 11:29am
tags:
AstraZeneca, breast cancer, Merck, Lynparza
Trump says "big discussion" over childhood vaccine programs is coming
Axios
Thursday, December 12, 2024 - 11:27am
tags:
Donald Trump, vaccines, Robert F Kennedy Jr.
Satellos doses first DMD subject in Phase Ib trial
Clinical Trials Arena
Thursday, December 12, 2024 - 11:26am
tags:
Satellos Bioscience, DMD, clinical trials, SAT-3247
Corcept's cortisol modulator fails to slow ALS decline
Fierce Biotech
Thursday, December 12, 2024 - 11:23am
tags:
Corcept Therapeutics, ALS, clinical trials
Bavarian Nordic plans to shut down San Diego R&D site, lay off 48 employees
Fierce Biotech
Wednesday, December 11, 2024 - 10:51pm
tags:
Bavarian Nordic, San Diego, R&D, layoffs
Reverse, reverse: Liver disease biotech Hepion and Pharma Two B call off merger
Fierce Biotech
Wednesday, December 11, 2024 - 10:49pm
tags:
M&A, Hepion Pharmaceuticals, Pharma Two B, liver disease
Seaport Therapeutics sees success with allopregnanolone prodrug
Clinical Trials Arena
Wednesday, December 11, 2024 - 10:46pm
tags:
Seaport Therapeutics, allopregnanolone, SPT-300, clinical trials
Eli Lilly is going to test Zepbound as a treatment for addiction
Quartz
Wednesday, December 11, 2024 - 10:44pm
tags:
Eli Lilly, David Ricks, Zepbound, addiction, alcohol-use disorder
New bipartisan legislation would force insurers, PBMs to sell pharmacy businesses
Healthcare Dive
Wednesday, December 11, 2024 - 10:41pm
tags:
legistation, PBMs, CVS Health, Cigna, UnitedHealth
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wednesday, December 11, 2024 - 11:40am
tags:
Gilead Sciences, Biktarvy, patent cliffs, HIV
Walgreens shares surge on reported talks to be taken private
Axios
Wednesday, December 11, 2024 - 11:31am
tags:
Walgreens, pharmacies, private equity
How the Omnicom-IPG merger could reshape pharma marketing
Medical Marketing and Media
Wednesday, December 11, 2024 - 11:29am
tags:
pharma marketing, Omnicom, IPG, M&A
How Trump’s second term will affect the medtech industry
Medtech Dive
Wednesday, December 11, 2024 - 11:28am
tags:
Medtech, Donald Trump, tarriffs, M&A, CDRH, LDTs

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.